BRPI0612169A2 - métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação - Google Patents

métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação Download PDF

Info

Publication number
BRPI0612169A2
BRPI0612169A2 BRPI0612169-1A BRPI0612169A BRPI0612169A2 BR PI0612169 A2 BRPI0612169 A2 BR PI0612169A2 BR PI0612169 A BRPI0612169 A BR PI0612169A BR PI0612169 A2 BRPI0612169 A2 BR PI0612169A2
Authority
BR
Brazil
Prior art keywords
methods
lung cancer
determination
polynucleotides
articles
Prior art date
Application number
BRPI0612169-1A
Other languages
English (en)
Inventor
Robert L Yauch
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0612169A2 publication Critical patent/BRPI0612169A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS PROGNóSTICOS, MéTODOS DE DETECçãO, DE DISTINçãO, DE IDENTIFICAçãO, DE DETERMINAçãO E DE MONITORAMENTO RELACIONADOS COM CáNCER DE PULMãO, MéTODOS PARA AMPLIFICAçãO DE UM áCIDO NUCLéICO QUE CODIFICA C-MET HUMANO, BIOMARCADORES DE CáNCER DE PULMãO, AGENTES DE IMAGEM DE CáNCER DE PULMãO, POLINUCLEOTIDEOS, AGENTES DE LIGAçãO DE ANTIGENO, CONJUNTOS, MEIOS LEGIVEIS EM COMPUTADOR E KITS E/OU ARTIGOS DE FABRICAçãO. A presente invenção fornece métodos e composições úteis para detectar mutações em c-met em células de câncer de pulmão.
BRPI0612169-1A 2005-03-25 2006-03-24 métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação BRPI0612169A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66531705P 2005-03-25 2005-03-25
PCT/US2006/010851 WO2006104912A2 (en) 2005-03-25 2006-03-24 C-met mutations in lung cancer

Publications (1)

Publication Number Publication Date
BRPI0612169A2 true BRPI0612169A2 (pt) 2010-10-19

Family

ID=36512935

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612169-1A BRPI0612169A2 (pt) 2005-03-25 2006-03-24 métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação

Country Status (13)

Country Link
US (2) US20060263808A1 (pt)
EP (1) EP1861513A2 (pt)
JP (1) JP2008533991A (pt)
KR (1) KR20080004514A (pt)
CN (1) CN101180410A (pt)
AU (1) AU2006229990A1 (pt)
BR (1) BRPI0612169A2 (pt)
CA (1) CA2600283A1 (pt)
IL (1) IL185666A0 (pt)
MX (1) MX2007011650A (pt)
RU (1) RU2007139516A (pt)
WO (1) WO2006104912A2 (pt)
ZA (1) ZA200707946B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561211A (en) * 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
US20080160533A1 (en) * 2006-11-30 2008-07-03 Abbott Laboratories Assay for prediction of response to Met antagonists
US20100062441A1 (en) * 2007-03-15 2010-03-11 Ravi Salgia C-met mutations and uses thereof
JP2013507989A (ja) 2009-10-26 2013-03-07 アボット・ラボラトリーズ 非小細胞肺癌の予後に関連する染色体異常の検出
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101404682B1 (ko) * 2012-01-09 2014-06-10 사회복지법인 삼성생명공익재단 절단 가능한 프로브를 이용한 ｃ―Ｍｅｔ 유전자 검출 방법
KR101753833B1 (ko) 2012-01-09 2017-07-05 사회복지법인 삼성생명공익재단 절단 가능한 프로브를 이용한 만성골수성백혈병 유전자의 멀티플렉스 검출 방법
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3221468B1 (en) * 2014-11-20 2020-03-25 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
CN113150147A (zh) 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
CN105713987A (zh) * 2016-04-25 2016-06-29 北京福安华生物科技有限公司 一种检测人类met基因14外显子剪接突变的引物、探针及试剂盒
KR20190033513A (ko) * 2016-06-07 2019-03-29 익스프레션 패톨로지, 인크. Met 단백질에서 엑손 14 결실의 검출
KR101977351B1 (ko) * 2016-09-21 2019-05-10 사회복지법인 삼성생명공익재단 항암제 저항성 또는 민감성 예측용 조성물
CN106757379B (zh) * 2016-12-20 2018-08-28 上海赛安生物医药科技股份有限公司 肺癌多基因变异文库构建方法
GB201714748D0 (en) * 2017-09-13 2017-10-25 Univ Oxford Innovation Ltd Single-molecule phenotyping and sequencing of nucleic acid molecules
CN108315431A (zh) * 2018-05-04 2018-07-24 良培基因生物科技（武汉）有限公司 数字PCR技术检测c-MET基因扩增的引物、探针及其检测方法
CN108893536B (zh) * 2018-07-13 2022-02-15 江苏省人民医院（南京医科大学第一附属医院） 一种从人外周血CTC中检测c-MET基因拷贝数变异的方法和试剂盒
CN108929908A (zh) * 2018-07-17 2018-12-04 张丽英 一种基于数字PCR平台c-MET基因Exon14跳读的检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014772A3 (en) * 1996-04-05 2009-05-27 Antonio Giordano Method for the diagnosis and prognosis of cancer
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
JP2005536190A (ja) * 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2005001486A1 (en) * 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation

Also Published As

Publication number Publication date
CA2600283A1 (en) 2006-10-05
AU2006229990A1 (en) 2006-10-05
ZA200707946B (en) 2009-02-25
US20060263808A1 (en) 2006-11-23
IL185666A0 (en) 2008-01-06
RU2007139516A (ru) 2009-04-27
US20090155807A1 (en) 2009-06-18
WO2006104912A3 (en) 2007-01-11
KR20080004514A (ko) 2008-01-09
WO2006104912A2 (en) 2006-10-05
JP2008533991A (ja) 2008-08-28
EP1861513A2 (en) 2007-12-05
CN101180410A (zh) 2008-05-14
MX2007011650A (es) 2008-01-16
AU2006229990A2 (en) 2006-10-05
WO2006104912A9 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
BRPI0612169A2 (pt) métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação
García-Giménez et al. Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory
WO2006119435A3 (en) Identification of cancer biomarkers and phosphorylated proteins
GB2478441A (en) Lung cancer biomarkers and uses thereof
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2008013910A3 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
NZ592365A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
BRPI0607508A2 (pt) métodos e ácidos nucléicos para análise de distúrbios proliferativos celulares
CY1119526T1 (el) Εμπλουτισμος και ταυτοποιηση εμβρυϊκων κυτταρων σε μητρικο αιμα και προσδετες για τετοια χρηση
NZ712746A (en) Methods and systems for assessing clinical outcomes
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
Rana Crime investigation through DNA methylation analysis: methods and applications in forensics
BR112012032537A2 (pt) biomarcadores de câncer de pulmão e suas utilizações
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
NZ599214A (en) Multigene prognostic assay for lung cancer
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
Malinaric et al. The role of novel bladder cancer diagnostic and surveillance biomarkers—what should a urologist really know?
WO2009083780A8 (en) Breast cancer expression profiling
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
BRPI0809958C1 (pt) conjunto de esferas para a detecção de uma cepa de hpv e/ou para diferenciação entre duas ou mais cepas de hpv, método para a preparação do referido conjunto de esferas, método para o diagnóstico de infecção por hpv, método para determinação do risco de um indivíduo humano desenvolver uma doença associada a uma ou mais cepas de hpv e par de iniciadores para amplificação de oligonucleotídeo direcionado ao hpv oncogênico
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2019024579A1 (zh) 用于检测肺癌的基因标志物、试剂盒及肺癌检测方法
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]